Companies: 10,795·Total market cap: $144.5T

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc.

CLDXNASDAQHealthcare● Active

$28.54

$-0.08(-0.28%)

Market Cap$1.9B

P/E Ratio—

52W High$35.79

52W Low$19.25

Avg Volume958K

Open$28.87

Beta0.93

Net Income Financials Revenue

Celldex Therapeutics, Inc. (CLDX) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CLDX · net income · updated Jun 8, 2026

Core profitability metrics

CLDX · net income · margin · TTM · CAGR

Net income was −$258.8M for FY2025 (fiscal year ending 2025-12-31), down 63.9% year-over-year. Net profit margin was -17253.3%.

FY2025 Net Income−$258.8M▼ -63.9% YoY

Trailing 12M (TTM)−$283.7Mtrailing 4 quarters sum

Net Profit Margin< −999%−$258.8M ÷ $1.5M

YoY Change-63.9%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · CLDX net income history · CLDX profit margin

Annual net income data

CLDX · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$258.8M▼ 63.9%-17253.3%$1.5M

FY2024Loss−$157.9M▼ 11.6%-2248.8%$7.0M

FY2023Loss−$141.4M▼ 25.9%-2054.8%$6.9M

FY2022Loss−$112.3M▼ 59.3%-4765.6%$2.4M

FY2021Loss−$70.5M▼ 18.0%-1516.0%$4.7M

Net income vs peers (Healthcare)

CLDX vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

#1

Celldex Therapeutics, Inc.YOU

CLDX

−$258.8M-63.9%-17253.3%

Loss

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Celldex Therapeutics, Inc. (CLDX) reported net income of −$258.8M for FY2025 (fiscal year ending 2025-12-31), down 63.9% year-over-year. The net profit margin was -17253.3% — meaning the company kept $-172.53 of every dollar of revenue as profit.

Celldex Therapeutics, Inc. has not yet achieved annual profitability based on available data (15 fiscal years). The company has reported net losses across all available periods.

Celldex Therapeutics, Inc.'s net profit margin was -17253.3% for FY2025, based on the latest annual results.

Investors sometimes search for "Celldex Therapeutics, Inc. net worth" — the company's market capitalization is a separate figure from CLDX net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CLDX net income · 4 questions

Celldex Therapeutics, Inc. is not currently profitable on an annual basis. The company reported a net loss of $258.8M for FY2025.

is CLDX profitabledoes CLDX make a profitCLDX profitabilityCLDX profitable company

▸ Source: FMP /income-statement · GAAP · Celldex Therapeutics, Inc. · Celldex Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026